NULL

AURELIUS completes acquisition of LloydsPharmacy’s parent company, McKesson UK

07.04.2022

AURELIUS completes acquisition of LloydsPharmacy’s parent company, McKesson UK

Luxembourg/London, April 07, 2022 – AURELIUS is pleased to announce that it has successfully closed the acquisition of McKesson UK. McKesson UK is the parent company of a number of market leading healthcare businesses including LloydsPharmacy, John Bell & Croyden and AAH Pharmaceuticals. This landmark deal marks the fifth completed transaction in less than a year for AURELIUS European Opportunities IV, controlling a 70 % stake and its Co-Investor AURELIUS Equity Opportunities SE & Co. KGaA (ISIN: DE000A0JK2A8), controlling the remaining 30 %.

McKesson UK comprises four divisions and holds a substantial market share across each vertical: retail, digital, homecare and wholesale. McKesson UK’s success has been underpinned by its strong LloydsPharmacy brand, its loyal customer base and its leading commercial footprint across wholesale pharmaceuticals. Over recent years, the company has benefited from the introduction of additional services delivered across its more than 1,300 pharmacies, a growing digital offering and the ability to support the increasing trend of primary care being delivered to patients in their home.

AURELIUS will ensure a smooth transition as McKesson UK separates from its former US-based parent company, McKesson Corporation. Furthermore, AURELIUS will seek to leverage McKesson UK’s established market positions to maximise the opportunities available within each division.

AURELIUS was advised by Rothschild & Co. (Corporate Finance), PwC and FRP (Financial), Interpath (Tax), Mayer Brown and DLA (Legal), Cardano (Pensions), Kearney (IT) and Mansfield (Commercial).

Legal Information

The information on this website is for informational purposes only. The information on this website is not, and is not intended to be, investment advice nor is it a recommendation to enter into any investment; investors should seek independent investment advice before making any investment decisions. The information on this website does not constitute an offer to buy or sell any investment product or service or to engage in any investment activity, or a solicitation of any investment product or service in any jurisdiction in which Aurelius is not permitted to provide its services or make available any investment product.

Any investment opportunities that Aurelius makes available from time to time will only be available to professional investors and will be subject to separate terms and conditions which will apply. This website and the contents herein are only available to such investors in jurisdictions where Aurelius is permitted to offer its products or services. No other person may rely on the information contained in this website.

For UK recipients

This website has been communicated by Aurelius Investment Advisory Limited (“Aurelius”), an authorised representative for its principal Mirabella Advisers LLP, which is authorized and regulated by the Financial Conduct Authority, FCA FRN 606792.

This website is directed at only those entities who are investment professionals with professional experience in matters relating to the contents of this website or other persons who would be classified as professional investors or eligible counterparties pursuant to the rules of the Financial Conduct Authority. In particular, this website is not available to, and may not be relied on by, any person who is a retail investor. If you are in any doubt as to whether you would be deemed to be a retail investor, please seek professional advice and refrain from accessing this website until such advice has been received.